Circle Pharma discovers macrocycle medicines for cancer and other serious diseases using its MXMO platform, which combines computational, structure-based design with synthetic chemistry to create cell-permeable compounds against difficult protein targets. Its lead programs are investigational and at discovery or preclinical stages.
NI
Nextech Invest
Activity from announced rounds
Activity in this selectionOct 17, 2026 · Jul 20, 2026
Nextech Invest is the investment manager whose official portfolio includes Khartis, Parabilis and Circle Pharma.
Recorded funding activity
Circle develops macrocycle medicines. Khartis develops oral treatments for immune and chronic diseases, while Parabilis targets difficult cancer proteins. These are distinct drug-development programs within the recorded company history.
Sources
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 1 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $142.5M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionCircle Pharma, Inc.
$92.5MSeries E
ParticipantKhartis Therapeutics
Develops oral small molecule therapies for immunological and chronic diseases
$50MSeries B
Role not disclosed